Trial Profile
The evaluation of efficacy and safety in modification to new immunosuppressant (tacrolimus hydrate:Graceptor) from the current immunosuppressive therapy after liver transplantation
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2014
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Liver transplant rejection
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Astellas Pharma
- 10 Feb 2014 New trial record